Welcome to our dedicated page for UNITEDHEALTH GROUP SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITEDHEALTH GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITEDHEALTH GROUP's regulatory disclosures and financial reporting.
Form 4 overview: UnitedHealth Group Inc. (UNH) reported one insider transaction by Patrick H. Conway, Chief Executive Officer of Optum. On 24 June 2025, Conway acquired 73.058 shares of common stock at a stated price of $0.00. The shares represent dividend equivalents that accrue on previously granted restricted stock units (RSUs); they will vest or be forfeited under the same conditions as the underlying RSUs.
Following the credit, Conway’s total beneficial ownership increased to 10,471.511 shares, held in direct form. No derivative securities were reported in this filing, and there were no dispositions or sales.
Key points for investors:
- The transaction is non-open-market and mechanically linked to existing RSUs, signalling neither an active purchase nor a sale decision.
- The share increase is immaterial—about 0.7% of Conway’s reported holdings and negligible relative to UnitedHealth’s ~930 million shares outstanding.
- No Rule 10b5-1 trading plan was indicated, and there are no signs of strategic shifts, financing activities, or performance commentary in the filing.
Overall, the Form 4 reflects routine compensation-related activity with neutral implications for UnitedHealth shareholders.
Form 4 filing overview for UnitedHealth Group Inc. (UNH)
Chief Accounting Officer Thomas E. Roos reported a small automatic acquisition of company stock on 24 June 2025. The filing discloses the crediting of 25.252 dividend-equivalent shares tied to previously granted restricted stock units (RSUs). These shares were received at $0 cost, consistent with the dividend-equivalent feature of the RSUs. Following the transaction, Roos’ direct beneficial ownership increased to 29,524.318 common shares.
No derivative securities were acquired or disposed of, and there were no open-market purchases or sales. The transaction code “A” confirms it was an acquisition rather than a sale, and the explanation section clarifies that the shares will forfeit if the underlying RSUs fail to vest.
Investor takeaway: The filing reflects routine dividend-equivalent accretion and signals continued alignment of the senior officer’s compensation with shareholder returns, but the volume (<1% of the insider’s holdings) is immaterial to UNH’s share float and is unlikely to influence market sentiment.
Transaction details: On 24 June 2025 UnitedHealth Group Inc. (UNH) director Michele J. Hooper received 266 shares of UNH common stock, as disclosed in a Form 4 filed with the SEC on 26 June 2025. The shares were credited as dividend equivalents on previously vested deferred stock units (DSUs); accordingly, no cash consideration was paid (transaction price reported as $0) and no open-market trade occurred.
Post-transaction ownership: Following the award, Ms. Hooper's direct ownership increased to 40,306 shares. No derivative securities were acquired or disposed, and there were no sales. The filing indicates direct ownership (box "D") and does not reference a Rule 10b5-1 trading plan.
Investor context: A 266-share increment represents less than 1% of Ms. Hooper's holdings and is immaterial relative to UnitedHealth's roughly 930 million outstanding shares. Such dividend-equivalent accruals are routine for deferred equity awards and generally signal neither bullish nor bearish sentiment. The filing does, however, reaffirm the director's continuing equity alignment with shareholders.
Insider activity: On 24 Jun 2025, UnitedHealth Group (UNH) director and former CEO Stephen J. Hemsley reported the credit of 55 common shares at $0 cost, reflecting dividend-equivalent units paid on previously vested deferred stock units. These shares were immediately vested and subject to the same terms as the underlying units. Following the credit, Hemsley’s direct holdings rose to roughly 374,407.942 shares, alongside 347.29 shares held through a 401(k) plan and 735,115 shares held via family trusts. No derivative securities were exercised, and the filing does not reference a Rule 10b5-1 trading plan. The adjustment is routine, immaterial relative to Hemsley’s more than 1.1 million-share beneficial stake, and is unlikely to influence market perception or valuation.
On June 26, 2025, UnitedHealth Group Incorporated (UNH) filed a Form 4 disclosing that director Kristen L. Gil acquired 7 shares of common stock on June 24, 2025. The acquisition was coded "A" and carried a price of $0 per share because the shares represent dividend equivalents paid on vested deferred stock units.
Following the transaction, Gil directly owns 1,558 shares and indirectly holds 3,800 shares through a trust. No derivative securities were reported. The transaction is routine and immaterial to UnitedHealth's float but modestly increases insider alignment with shareholders.
UnitedHealth Group Inc. (UNH) – Form 4 filing dated 26-Jun-2025
Director John H. Noseworthy reported the automatic acquisition of 42 shares of common stock on 24-Jun-2025. The shares represent dividend equivalents on previously vested deferred stock units and were credited at a transaction price of $0.00. Following this routine credit, Noseworthy’s direct ownership rises to 6,105 shares. No derivative transactions or dispositions were reported, and the filing indicates the transaction was not executed under a Rule 10b5-1 trading plan. The small share count and zero-cost basis signal an administrative, non-market purchase with limited impact on public float or insider sentiment.
UnitedHealth Group director Paul R. Garcia reported insider trading activity on June 24, 2025. The transaction involved the acquisition of 11 shares of Common Stock as dividend equivalents paid on vested deferred stock units, received at $0 price.
Following the transaction, Garcia's beneficial ownership consists of:
- 2,481 shares held directly
- 2,146 shares held indirectly through a Revocable Trust
- 45 shares held indirectly through Trust 2
- 55 shares held indirectly through Trust 3
The dividend equivalents were immediately vested and are subject to the same terms as the underlying deferred stock units. The Form 4 was filed by attorney-in-fact Faraz A. Choudhry on June 26, 2025.
UnitedHealth Group Inc. (UNH) filed a Form 4 reporting a routine ownership update for Christopher R. Zaetta, EVP & Chief Legal Officer. On 06/24/2025, Zaetta acquired 48.038 common shares at a stated price of $0, representing dividend-equivalent units credited on outstanding restricted stock units (RSUs). These dividend equivalents carry the same vesting conditions as the underlying RSUs and are forfeited if those units fail to vest. Following the credit, Zaetta’s direct beneficial ownership stands at 10,240.746 shares. No derivatives were reported, and there were no dispositions of shares.
UnitedHealth Group Inc. (UNH) – Form 4 filing, 26 Jun 2025: President & CFO John F. Rex reported an automatic acquisition of 131.931 common shares on 24 Jun 2025. The shares represent dividend-equivalent units credited on outstanding restricted stock units; no cash outlay was made (price = $0).
Following the credit, Rex directly owns 203,898.467 shares and indirectly owns 6,791 shares via a trust. No derivative transactions, open-market purchases, or sales were disclosed. The filing is routine and does not reflect a discretionary investment decision.